These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 37697370)
1. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress. She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370 [TBL] [Abstract][Full Text] [Related]
2. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701 [TBL] [Abstract][Full Text] [Related]
3. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Palam LR; Gore J; Craven KE; Wilson JL; Korc M Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962 [TBL] [Abstract][Full Text] [Related]
4. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669 [TBL] [Abstract][Full Text] [Related]
5. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Xu L; Ma X; Zhang X; Zhang C; Zhang Y; Gong S; Wu N; Zhang P; Feng X; Guo J; Zhao M; Ren Z; Zhang P Mol Cancer; 2023 Dec; 22(1):195. PubMed ID: 38044421 [TBL] [Abstract][Full Text] [Related]
6. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726 [TBL] [Abstract][Full Text] [Related]
8. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Wu L; Ge Y; Yuan Y; Li H; Sun H; Xu C; Wang Y; Zhao T; Wang X; Liu J; Gao S; Chang A; Hao J; Huang C Cancer Lett; 2022 Nov; 548():215864. PubMed ID: 35981571 [TBL] [Abstract][Full Text] [Related]
10. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism. Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382 [TBL] [Abstract][Full Text] [Related]
12. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886 [TBL] [Abstract][Full Text] [Related]
13. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Li Z; Ge Y; Dong J; Wang H; Zhao T; Wang X; Liu J; Gao S; Shi L; Yang S; Huang C; Hao J Gastroenterology; 2022 Apr; 162(4):1256-1271.e14. PubMed ID: 34951995 [TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma. Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093 [TBL] [Abstract][Full Text] [Related]
15. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
16. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Hu C; Xia R; Zhang X; Li T; Ye Y; Li G; He R; Li Z; Lin Q; Zheng S; Chen R Mol Cancer; 2022 Jan; 21(1):24. PubMed ID: 35045883 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261 [TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125 [TBL] [Abstract][Full Text] [Related]
19. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499 [TBL] [Abstract][Full Text] [Related]
20. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect. Hou Y; Zhang Q; Pang W; Hou L; Liang Y; Han X; Luo X; Wang P; Zhang X; Li L; Meng X Cell Death Differ; 2021 Nov; 28(11):3105-3124. PubMed ID: 34021267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]